Maintenance of weight loss: Once therapeutic levels have helped patients achieve their goal weight, lowering the dose may be a helpful, longer-term approach to maintaining it
So far, very little is known about how GLP-1 use or misuse affects people who binge or restrict food, despite the prevalence of those behaviors
Combining these agents poses unpredictable risks to glucose metabolism, as tesamorelin raises GH and can induce insulin resistance, potentially opposing retatrutide's glycaemic effects
They slow gastric emptying, reduce cravings, and help you feel full longer
Furthermore, direct comparisons of GLP-1RAs and exercise in diverse populations are scarce, and evidence on optimal sequencing, duration, and integration of hybrid interventions remains limited ( Beyond physiological adaptations, treatment adherence and long-term success largely depend on motivation, self-efficacy, and body-image perception, which may fluctuate during pharmacologic weight loss (63)
Diabetes 26:525529 Lund PK (2005) The discovery of glucagon-like peptide 1